Clinical Trial Detail

NCT ID NCT02578680
Title Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Merck Sharp & Dohme Corp.
Indications

lung non-small cell carcinoma

Therapies

Carboplatin + Pemetrexed Disodium

Carboplatin + Pembrolizumab + Pemetrexed Disodium

Cisplatin + Pembrolizumab + Pemetrexed Disodium

Cisplatin + Pemetrexed Disodium

Age Groups: adult senior

Additional content available in CKB BOOST